[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 240, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1278804, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric J. Warren R.Ph.", "age": 51, "title": "Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 718859, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 37, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 65, "title": "Chief Technical Operations Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 41, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 550350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.175, "open": 2.14, "dayLow": 2.12, "dayHigh": 2.23, "regularMarketPreviousClose": 2.175, "regularMarketOpen": 2.14, "regularMarketDayLow": 2.12, "regularMarketDayHigh": 2.23, "beta": 0.954, "forwardPE": 10.161942, "volume": 4354421, "regularMarketVolume": 4354421, "averageVolume": 5586268, "averageVolume10days": 10971180, "averageDailyVolume10Day": 10971180, "bid": 2.15, "ask": 2.21, "bidSize": 1400, "askSize": 1700, "marketCap": 431506688, "fiftyTwoWeekLow": 1.58, "fiftyTwoWeekHigh": 3.94, "priceToSalesTrailing12Months": 1.4605017, "fiftyDayAverage": 2.4006, "twoHundredDayAverage": 2.2367, "currency": "USD", "enterpriseValue": 555752000, "profitMargins": -0.29369, "floatShares": 195632281, "sharesOutstanding": 197035008, "sharesShort": 30492669, "sharesShortPriorMonth": 33463960, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.1548, "heldPercentInsiders": 0.00481, "heldPercentInstitutions": 0.66339993, "shortRatio": 5.7, "shortPercentOfFloat": 0.1552, "impliedSharesOutstanding": 197035008, "bookValue": -1.894, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -86771000, "trailingEps": -0.67, "forwardEps": 0.2, "enterpriseToRevenue": 1.881, "enterpriseToEbitda": 33.688, "52WeekChange": -0.15891474, "SandP52WeekChange": 0.2421279, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ESPR", "underlyingSymbol": "ESPR", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "firstTradeDateEpochUtc": 1372253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "00314c6d-38c1-3c8e-a318-bd51d9ba1c8c", "messageBoardId": "finmb_28236", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.19, "targetHighPrice": 16.0, "targetLowPrice": 2.05, "targetMeanPrice": 7.50833, "targetMedianPrice": 6.5, "recommendationMean": 2.14286, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 144716992, "totalCashPerShare": 0.734, "ebitda": 16497000, "totalDebt": 268961984, "quickRatio": 1.281, "currentRatio": 1.854, "totalRevenue": 295451008, "revenuePerShare": 1.776, "returnOnAssets": 0.03842, "freeCashflow": -8951375, "operatingCashflow": -25758000, "revenueGrowth": 0.52, "grossMargins": 0.6364, "ebitdaMargins": 0.05584, "operatingMargins": -0.31039, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-21"}]